Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy

Area of Science:

• Nephrology
• Molecular Biology
• Cell Biology

Background:

• Polycystic kidney diseases (PKDs) are genetic disorders characterized by kidney cyst formation with no current effective treatments.
• Dysfunctional cilia and aberrant cell cycle regulation are identified as key triggers of cystogenesis in PKD.
• Therapeutic strategies targeting cell cycle dysregulation are needed.

Purpose of the Study:

• To investigate the therapeutic potential of cyclin-dependent kinase (CDK) inhibition using roscovitine in polycystic kidney disease (PKD).
• To elucidate the molecular mechanisms underlying CDK inhibitor action in arresting cystogenesis.
• To evaluate the efficacy of CDK inhibition in preserving renal function and epithelial differentiation.

Main Methods:

• Utilized mouse models of both slowly progressive and aggressive polycystic kidney disease (PKD).
• Administered the CDK inhibitor roscovitine to assess its impact on cystogenesis and renal function.
• Performed molecular analyses to examine cell cycle arrest, transcriptional changes, apoptosis, cAMP levels, and aquaporin 2 expression.

Main Results:

• CDK inhibition with roscovitine demonstrated robust and sustained arrest of cystogenesis in PKD mouse models.
• Treatment led to effective cell cycle arrest, reduced transcription, and attenuated apoptosis.
• Roscovitine treatment preserved renal function and downregulated cAMP and aquaporin 2, indicating preserved epithelial differentiation.

Conclusions:

• Therapeutic correction of cell cycle dysregulation via CDK inhibition is a promising strategy for treating polycystic kidney disease (PKD).
• CDK inhibition effectively halts cystogenesis, preserves renal function, and may restore epithelial differentiation.
• Targeting the coordinated regulation of proliferation and apoptosis presents a viable therapeutic approach for diverse renal diseases.